— Report will be subject of Midwest CEPAC meeting in September; Open Input now being accepted until March 12, 2019 — BOSTON, February 22, 2019 – The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of icosapent ethyl (Vascepa®, Amarin Pharma) and rivaroxaban (Xarelto®, […]
Read More
02/22/2019
— Independent appraisal committee votes that rivaroxaban and icosapent ethyl improve patient health at prices that achieve good long-term value for money, but the large potential short-term budget impact associated with treating even a small percentage of eligible US patients leads ICER to issue an Access and Affordability Alert — BOSTON, October 17, 2019 – The […]
Read More
10/17/2019
–Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds if priced between $2,300 and $4,000 per year, depending on population– BOSTON, February 15, 2019 – The Institute for Clinical and Economic Review (ICER) today released a Final New Evidence Update for alirocumab (Praluent®, Regeneron/Sanofi), an injectable PCSK9 inhibitor used […]
Read More
02/15/2019
— Report will be subject of a Midwest CEPAC meeting in February 2021; Open Input now being accepted until June 30, 2020 — BOSTON, June 12, 2020 – The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, Esperion Therapeutics, […]
Read More
06/12/2020
Public Comments
Closed